(SUPN) Supernus Pharmaceuticals, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(SUPN) Supernus Pharmaceuticals, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This Supernus Pharmaceuticals, Inc. BCG Matrix is a company-specific strategic tool used to assess the portfolio across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
Qelbree, ADHD ages 6 to 17
Qelbree is Supernus Pharmaceuticals, Inc.’s main growth brand and is approved for ADHD in children and adolescents ages 6 to 17. It sits in a large CNS market, where Supernus has kept growing prescriptions, so it fits the Star role in the BCG matrix going into end-2025. For BCG, this is the clearest high-growth, high-share asset in the portfolio.
GOCOVRI, Parkinson’s dyskinesia
GOCOVRI is Supernus Pharmaceuticals, Inc.'s niche neurology Star: it treats levodopa-induced dyskinesia, a movement side effect that can affect long-term Parkinson’s patients. Parkinson’s disease affects nearly 1 million people in the U.S., and about 90,000 new cases are diagnosed each year, leaving room for deeper use. Its recurring use profile and focused patient base support steady growth.
MYOBLOC, botulinum toxin Type B
MYOBLOC, a botulinum toxin Type B, is approved for adult cervical dystonia and sialorrhea, so it sits in a durable specialty niche with repeat injection cycles. Its established use and specialist prescribing support steady demand, even in a mature market. Supernus Pharmaceuticals, Inc. can treat it as a Star if recent sales growth and share gains stay ahead of the broader neurology injectables market.
Non-stimulant ADHD franchise
Supernus Pharmaceuticals, Inc. has a real non-stimulant ADHD niche through Qelbree, and that matters because demand for ADHD options that avoid stimulant risks stays strong. In a market where non-stimulants still take a small share versus stimulants, a differentiated CNS franchise can keep building share and pricing power.
That makes this a Star-like asset: it sits in a growing category and Supernus Pharmaceuticals, Inc. has one of the few meaningful presences there. If uptake keeps rising, the franchise can scale into a larger share of Supernus Pharmaceuticals, Inc. revenue over time.
- Qelbree anchors the non-stimulant ADHD franchise.
- Demand for alternatives remains structurally high.
- Growth runway supports Star classification.
US neurology specialty sales platform
Supernus Pharmaceuticals, Inc. uses a focused U.S. neurology sales platform that sells through wholesalers, specialty pharmacies, and authorized distributors. That setup fits complex CNS brands, where access and targeted promotion matter more than broad retail reach.
In BCG terms, this is a support asset that can help "Stars" scale faster by lowering launch friction and improving payer and prescriber reach. The model is built to keep neurology brands close to specialists, not spread sales effort thin.
- Focused neurology reach
- Three-channel U.S. access model
- Supports faster brand uptake
Qelbree Leads Supernus’s CNS Growth Story
Qelbree is Supernus Pharmaceuticals, Inc.’s clearest Star because it leads the company’s growth in a large non-stimulant ADHD market. GOCOVRI adds a second Star-like neurology niche, while MYOBLOC supports steady repeat demand in specialty care. Together, they give Supernus Pharmaceuticals, Inc. a focused CNS growth base.
| Star asset | Role | Key signal |
|---|---|---|
| Qelbree | Growth driver | Non-stimulant ADHD |
| GOCOVRI | Niche Star | Parkinsons side effects |
| MYOBLOC | Steady niche | Repeat specialist use |
What is included in the product
Detailed Word Document
BCG Matrix of Supernus Pharmaceuticals shows which drugs are Stars, Cash Cows, Question Marks, or Dogs, guiding invest/hold/divest decisions.
Editable Excel File
Clean BCG Matrix view of Supernus Pharmaceuticals, Inc. to quickly spot growth, cash, and drag.
Reference Sources
Provides a traceable source trail for Supernus Pharmaceuticals, Inc. that strengthens credibility and speeds investor due diligence.
Cash Cows
Trokendi XR, extended-release topiramate
Trokendi XR is a mature extended-release topiramate brand for epilepsy and migraine prevention. In BCG terms, it fits a Cash Cow: low growth, high cash conversion, and long-run residual demand even as generic pressure keeps sales shrinking. Its value is mainly in harvesting cash, not driving future growth.
Oxtellar XR, oxcarbazepine ER
Oxtellar XR (oxcarbazepine ER) is approved for partial-onset seizures in patients 6 years and older, so it serves a defined epilepsy niche rather than a fast-growth market. In 2025, Supernus Pharmaceuticals reported total revenue of about $600 million, and mature brands like this help fund cash flow with low growth needs. That makes Oxtellar XR a classic Cash Cow: steady demand, limited upside, and dependable support for the portfolio.
APOKYN, advanced Parkinson’s rescue therapy
APOKYN is Supernus Pharmaceuticals, Inc.'s rescue therapy for acute off episodes in advanced Parkinson’s disease, so it fits a narrow but recurring need. That makes it a classic Cash Cow: steady repeat use, low incremental marketing spend, and limited competition in a mature niche. Its value comes from reliable maintenance of an established patient base, not fast growth.
XADAGO, PD adjunct therapy
XADAGO, a safinamide add-on to levodopa/carbidopa for Parkinson’s off periods, sits in a small, mature niche with limited upside. That fits a Cash Cow: steady, established use, low growth, and likely modest but durable cash flow rather than a big expansion engine.
- Adjunct only, not core growth
- Targets PD off-periods
- Mature niche product
- Cash flow over expansion
Osmolex ER, PD and EPS treatment
Osmolex ER is an older branded CNS cash cow for Supernus Pharmaceuticals, Inc.: it is approved for Parkinson’s disease and drug-induced extrapyramidal reactions in adults, so the addressable market is narrow and expansion upside is limited. That said, mature branded demand can still throw off steady cash with low ongoing support costs.
Approved for PD and drug-induced EPS
Older brand, limited growth runway
Stable sales can fund cash flow
Low support spend helps margins
Supernus’ Cash Cows Keep the Revenue Engine Running
Supernus Pharmaceuticals, Inc.'s Cash Cows are mature CNS brands that still convert steady demand into cash. In 2025, Supernus Pharmaceuticals, Inc. reported about $600 million in revenue, and these products help fund the portfolio with low growth needs. Their value is cash generation, not expansion.
| Product | Role |
|---|---|
| Trokendi XR | Harvest cash |
| APOKYN | Stable niche |
| Osmolex ER | Low-growth cash |
Preview the Actual Deliverable
Supernus Pharmaceuticals, Inc. Reference Sources
You’re previewing the exact Supernus Pharmaceuticals, Inc. BCG Matrix document you’ll receive after purchase. The full file is the same professionally formatted version—no mockups, no watermark, no demo content. Once purchased, it’s ready for immediate download, editing, printing, or sharing. What you see here is exactly what you’ll own.
Dogs
Generic-pressured Trokendi XR
Generic-pressured Trokendi XR fits the Dogs bucket because topiramate ER now faces multiple generics, which has cut pricing power and eroded share. In Supernus Pharmaceuticals, Inc., this franchise offers limited growth and weak long-term economics versus higher-value products. With the market commoditized, revenue tends to stay under pressure instead of expanding.
Small-share Oxtellar XR
Oxtellar XR sits in a mature seizure market led by larger epilepsy brands, so its growth runway is narrow. Its low-single-digit share and niche use limit expansion, which fits Dog status in the BCG Matrix. Supernus Pharmaceuticals, Inc. is better off treating it as a cash-preservation brand than a growth engine.
Low-volume APOKYN
APOKYN fits the question mark-to-dog logic in Supernus Pharmaceuticals, Inc.’s BCG Matrix: it serves a narrow Parkinson’s rescue-use niche, so the addressable market is small. The U.S. has about 1 million people living with Parkinson’s disease, but APOKYN’s on-demand use keeps volume limited. That means low share, low growth, and weak scale economics.
Low-volume XADAGO
XADAGO is a small adjunctive Parkinson’s franchise, so it sits in Dog territory in BCG terms. Supernus has limited room to scale it because the drug serves a narrow add-on niche, not a broad chronic-use base. In 2025/2026 filings, Supernus did not show a large standalone growth engine here, which supports a low-share, low-growth view.
- Small Parkinson’s add-on market
- Limited expansion runway
- Low BCG strategic priority
Niche Osmolex ER use
Osmolex ER is a narrow-use brand for Parkinson’s disease and drug-induced extrapyramidal reactions, so its market stays small and the growth path is limited. In Supernus Pharmaceuticals, Inc.’s portfolio, that makes it a classic Dog: low-growth, niche demand, and only modest commercial traction. The asset is more of a tail product than a growth engine.
- Two labeled uses only
- Small addressable patient base
- Modest uptake limits scale
- Low-growth tail asset
Supernus’ Dogs: Niche Brands, Weak Growth, Cash Harvest
Dogs in Supernus Pharmaceuticals, Inc. are the low-share, low-growth brands: Trokendi XR faces generic erosion, Oxtellar XR is mature, and APOKYN, XADAGO, and Osmolex ER serve small niche markets. APOKYN is tied to a U.S. Parkinson’s pool of about 1 million people, but on-demand use keeps scale weak. These assets look better for cash harvest than growth.
| Brand | Dog signal | Key fact |
|---|---|---|
| Trokendi XR | Generic pressure | Multiple generics |
| APOKYN | Niche use | ~1M Parkinson’s patients |
Question Marks
SPN-830, late-stage PD device combo
SPN-830 is a late-stage drug-device combo for Parkinson’s off episodes, aimed at a large need: about 1 million people in the U.S. live with Parkinson’s, and roughly 40% to 50% develop motor fluctuations. It still faces FDA approval risk and then the harder test of uptake. That mix of high need, high uncertainty, and possible upside fits a Question Mark.
SPN-817, Phase I severe epilepsy
SPN-817 is still in Phase I for severe epilepsy, so it has no commercial share yet and carries very high clinical risk. At this stage, Supernus Pharmaceuticals, Inc. must fund early testing before any proof of efficacy, safety, or market value. Phase I assets like this are classic Question Marks in the BCG Matrix because success is uncertain and cash needs are high.
SPN-820, Phase II resistant depression
SPN-820 is in Phase II for treatment-resistant depression, a market affecting about 30% of major depressive disorder patients. The opportunity is large, but Supernus Pharmaceuticals, Inc. has not yet shown clinical proof, so the asset stays a Question Mark in BCG terms. If Phase II data improve, it could shift toward Star status; if not, it likely stays low-value.
SPN-443, preclinical CNS program
SPN-443 is a preclinical CNS asset, so it has no human efficacy data, no approved label, and effectively 0% market share today. In BCG terms, that puts it in Question Marks: high scientific upside, but also a high chance of failure before any sales can start. For Supernus Pharmaceuticals, Inc., value here depends on whether early data can justify moving into clinical testing.
- Preclinical only
- No human proof yet
- Zero current market share
- High-upside, high-risk asset
SPN-446, preclinical CNS program
SPN-446 is a preclinical CNS program, so it fits the Question Mark bucket: high scientific upside, but no clear path to revenue yet. As of Supernus Pharmaceuticals, Inc.'s latest reported 2025 results, the Company generated $661.8 million in total revenue, but SPN-446 has not advanced far enough to move the needle today. Preclinical assets like this need proof-of-concept data before they can justify more capital.
- Early stage, no commercialization yet
- Potential upside, but high failure risk
- Needs clinical data to re-rate
Supernus’ Early CNS Bets: High Upside, No Sales Yet
Supernus Pharmaceuticals, Inc. Question Marks are its early CNS bets: SPN-830, SPN-817, SPN-820, SPN-443, and SPN-446. They have high upside but no current market share, and all depend on clinical or FDA proof before they can add sales; Supernus Pharmaceuticals, Inc. reported $661.8 million in 2025 revenue, so these assets are still value drivers only in the future.
| Asset | Stage | Status |
|---|---|---|
| SPN-830 | Late stage | Approval risk |
| SPN-817 | Phase I | Very high risk |
| SPN-820 | Phase II | Unproven |
| SPN-443 | Preclinical | No human data |
| SPN-446 | Preclinical | No revenue yet |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.